| 臺大學術典藏 |
2021-09-17T03:21:17Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:17Z |
Albers-Sch?nberg disease
|
Keng L.-T.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-09-17T03:21:16Z |
Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancer
|
Tsou P.-H.; Lin Z.-L.; Pan Y.-C.; Yang H.-C.; Chang C.-J.; SHENG-KAI LIANG; Wen Y.-F.; Chang C.-H.; Chang L.-Y.; Yu K.-L.; Liu C.-J.; Keng L.-T.; Lee M.-R.; Ko J.-C.; Huang G.-H.; Li Y.-K. |
| 臺大學術典藏 |
2021-09-17T03:21:16Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T03:21:16Z |
Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model
|
Chien L.-H.; Chen C.-H.; Chen T.-Y.; Chang G.-C.; Tsai Y.-H.; Hsiao C.-F.; Chen K.-Y.; Su W.-C.; Wang W.-C.; Huang M.-S.; Chen Y.-M.; Chen C.-Y.; SHENG-KAI LIANG; Chen C.-Y.; Wang C.-L.; Lee M.-H.; Chung R.-H.; Tsai F.-Y.; Hu J.-W.; Katki H.A.; Chatterjee N.; Chanock S.J.; Rothman N.; Lan Q.; Yang P.-C.; Chen C.-J.; Chang I.-S.; Hsiung C.A. |
| 臺大學術典藏 |
2021-09-17T03:21:15Z |
Pulmonary granulomas: Give it a whorl
|
Keng L.-T.; Lo W.-Y.; Huang H.-N.; Ko H.-J.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-09-17T03:21:15Z |
FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis
|
SHENG-KAI LIANG; Hsu C.-C.; Song H.-L.; Huang Y.-C.; Kuo C.-W.; Yao X.; Li C.-C.; Yang H.-C.; Hung Y.-L.; Chao S.-Y.; Wu S.-C.; Tsai F.-R.; Chen J.-K.; Liao W.-N.; Cheng S.-C.; Tsou T.-C.; Wang I.-C. |
| 臺大學術典藏 |
2021-09-17T03:21:15Z |
Functional Status After Pulmonary Rehabilitation as a Predictor of Weaning Success and Survival in Patients Requiring Prolonged Mechanical Ventilation
|
Keng L.-T.; SHENG-KAI LIANG; Tseng C.-P.; Wen Y.-F.; Tsou P.-H.; Chang C.-H.; Chang L.-Y.; Yu K.-L.; Lee M.-R.; Ko J.-C. |
| 臺大學術典藏 |
2021-07-29T03:09:26Z |
FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis
|
HSIANG-LIN SONG; SHENG-KAI LIANG; Chia-Chan Hsu; Yu-Chi Huang; CHUN-WEI KUO; Xiang Yao; Hui-Chen Yang; Yu-Ling Hung; Sheng-Yang Chao; Shun-Chi Wu; Feng-Ren Tsai; Jen-Kun Chen; Wei-Neng Liao; Shin-Chin Cheng; Tsui-Chun Tsou; I-Ching Wang |
| 臺大學術典藏 |
2021-07-21T23:21:17Z |
FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis
|
SHENG-KAI LIANG; Hsu, Chia Chan; HSIANG-LIN SONG; Huang, Yu Chi; CHUN-WEI KUO; Yao, Xiang; Li, Chien Cheng; Yang, Hui Chen; Hung, Yu Ling; Chao, Sheng Yang; Wu, Shun Chi; Tsai, Feng Ren; Chen, Jen Kun; Liao, Wei Neng; Cheng, Shin Chin; Tsou, Tsui Chun; Wang, I. Ching |
| 臺大學術典藏 |
2021-07-21T23:21:16Z |
Functional Status After Pulmonary Rehabilitation as a Predictor of Weaning Success and Survival in Patients Requiring Prolonged Mechanical Ventilation
|
LI-TA KENG; SHENG-KAI LIANG; Tseng, Chi Ping; Wen, Yueh Feng; PING-HSIEN TSOU; CHIA-HAO CHANG; LIH-YU CHANG; KAI-LUN YU; MENG-RUI LEE; JEN-CHANG KO |
| 臺大學術典藏 |
2021-07-20T07:54:39Z |
Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy
|
LIH-YU CHANG; LI-TA KENG; Chin-Chung Shu; Jason Yao-Ping Chen; SHENG-KAI LIANG; Ching-Kai Lin; LIH-YU CHANG; CHIA-HAO CHANG; Jann-Yuan Wang; Chong-Jen Yu; Li-Na Lee |
| 臺大學術典藏 |
2021-07-14T07:15:22Z |
Functional Status After Pulmonary Rehabilitation as a Predictor of Weaning Success and Survival in Patients Requiring Prolonged Mechanical Ventilation
|
JEN-CHUNG KO; LI-TA KENG; SHENG-KAI LIANG; PING-HSIEN TSOU; CHIA-HAO CHANG; LIH-YU CHANG; KAI-LUN YU; MENG-RUI LEE; Tseng, Chi-Ping ; Wen, Yueh-Feng |
| 臺大學術典藏 |
2021-07-14T07:15:21Z |
Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancer
|
JEN-CHUNG KO; PING-HSIEN TSOU; CHIEN-JEN CHANG; SHENG-KAI LIANG; CHIA-HAO CHANG; LIH-YU CHANG; KAI-LUN YU; LI-TA KENG; MENG-RUI LEE; Zong-Lin Lin ; Yu-Chiang Pan ; Hui-Chen Yang ; Yueh-Feng Wen ; Chia-Jung Liu ; Guan-Hua Huang and Yaw-Kuen Li |
| 臺大學術典藏 |
2021-04-21T23:30:28Z |
Exploring volatile organic compounds in breath for high-accuracy prediction of lung cancer
|
PING-HSIEN TSOU; Lin, Zong Lin; Pan, Yu Chiang; Yang, Hui Chen; CHIEN-JEN CHANG; SHENG-KAI LIANG; Wen, Yueh Feng; CHIA-HAO CHANG; LIH-YU CHANG; KAI-LUN YU; Liu, Chia Jung; LI-TA KENG; MENG-RUI LEE; JEN-CHANG KO; Huang, Guan Hua; Li, Yaw Kuen |
| 臺大學術典藏 |
2021-03-11T08:34:25Z |
Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: Clinical features and susceptibilities of the isolates
|
Lee M.-R.;Jen-Chang Ko;Liang S.-K.;Lee S.-W.;Yen D.H.-T.;Hsueh P.-R.; MENG-RUI LEE; JEN-CHANG KO; SHENG-KAI LIANG; Lee S.-W.; Yen D.H.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-03-11T08:34:22Z |
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
|
Pan C.-H.;Chang Y.-F.;Lee M.-S.;Wen B.-C.;Jen-Chang Ko;Liang S.-K.;Liang M.-C.; Pan C.-H.; Chang Y.-F.; Lee M.-S.; Wen B.-C.; JEN-CHANG KO; SHENG-KAI LIANG; Liang M.-C. |
| 臺大學術典藏 |
2021-03-11T08:34:21Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:34:19Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.;Lee M.-R.;Liao W.-Y.;Ho C.-C.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:18Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.;Jen-Chang Ko;Yang J.C.-H.;Shih J.-Y.; SHENG-KAI LIANG; JEN-CHANG KO; James Chih-Hsin Yang; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:34:15Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-09T08:07:35Z |
Pulmonary granulomas: Give it a whorl
|
WEI-YUNG LO; SHENG-KAI LIANG; LI-TA KENG; Hsien-Neng Huang , Huan-Jang Ko |
| 臺大學術典藏 |
2021-02-08T08:05:08Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Jen-Chung Ko;Sheng-Kai Liang;Li-Ta Keng;Chia-Hao Chang;Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu; JEN-CHUNG KO; SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu |
| 臺大學術典藏 |
2021-02-02T09:21:39Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen, Yueh Feng; MENG-RUI LEE; Yang, Ching Yao; JANN-YUAN WANG; JEN-CHUNG KO; JIN-YUAN SHIH; CHONG-JEN YU |
| 臺大學術典藏 |
2021-01-19T12:08:48Z |
Pulmonary granulomas: Give it a whorl
|
LI-TA KENG; WEI-YUNG LO; Hsien-Neng Huang; Ko, Huan Jang; SHENG-KAI LIANG |
